select a format

Single User License
USD 1500 INR 97530
Site License
USD 3000 INR 195060
Corporate User License
USD 4500 INR 292590


Request a quote
Request a Customized research
Request for Sample Report


Recent Viewed Reports

Why Ken Reasearch?


The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

Nabriva Therapeutics AG-Product Pipeline Review-2015

Nabriva Therapeutics AG-Product Pipeline Review-2015

  • Products Id :- GMDHC06848CDB
  • |
  • Pages: 26
  • |
  • March 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Nabriva Therapeutics AG-Product Pipeline Review-2015


Global Markets Direct's, 'Nabriva Therapeutics AG-Product Pipeline Review-2015', provides an overview of the Nabriva Therapeutics AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Nabriva Therapeutics AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Nabriva Therapeutics AG including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Nabriva Therapeutics AG's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Nabriva Therapeutics AG's pipeline products

Reasons To Buy

Evaluate Nabriva Therapeutics AG's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Nabriva Therapeutics AG in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Nabriva Therapeutics AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Nabriva Therapeutics AG and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Nabriva Therapeutics AG

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Nabriva Therapeutics AG and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@]

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

Nabriva Therapeutics AG Snapshot 4

Nabriva Therapeutics AG Overview 4

Key Information 4

Key Facts 4

Nabriva Therapeutics AG-Research and Development Overview 5

Key Therapeutic Areas 5

Nabriva Therapeutics AG-Pipeline Review 8

Pipeline Products by Stage of Development 8

Pipeline Products-Monotherapy 9

Nabriva Therapeutics AG-Pipeline Products Glance 10

Nabriva Therapeutics AG-Clinical Stage Pipeline Products 10

Phase II Products/Combination Treatment Modalities 10

Phase I Products/Combination Treatment Modalities 11

Nabriva Therapeutics AG-Early Stage Pipeline Products 12

Preclinical Products/Combination Treatment Modalities 12

Nabriva Therapeutics AG-Drug Profiles 13

lefamulin 13

Product Description 13

Mechanism of Action 13

R&D Progress 13

BC-7013 15

Product Description 15

Mechanism of Action 15

R&D Progress 15

Small Molecules to Inhibit 23S Ribosomal RNA for Infections 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

Nabriva Therapeutics AG-Pipeline Analysis 17

Nabriva Therapeutics AG-Pipeline Products by Target 17

Nabriva Therapeutics AG-Pipeline Products by Route of Administration 18

Nabriva Therapeutics AG-Pipeline Products by Molecule Type 19

Nabriva Therapeutics AG-Pipeline Products by Mechanism of Action 20

Nabriva Therapeutics AG-Recent Pipeline Updates 21

Nabriva Therapeutics AG-Dormant Projects 23

Nabriva Therapeutics AG-Locations And Subsidiaries 24

Head Office 24

Other Locations & Subsidiaries 24

Appendix 25

Methodology 25

Coverage 25

Secondary Research 25

Primary Research 25

Expert Panel Validation 25

Contact Us 25

Disclaimer 26

List of Tables

Nabriva Therapeutics AG, Key Information 4

Nabriva Therapeutics AG, Key Facts 4

Nabriva Therapeutics AG-Pipeline by Indication, 2015 7

Nabriva Therapeutics AG-Pipeline by Stage of Development, 2015 8

Nabriva Therapeutics AG-Monotherapy Products in Pipeline, 2015 9

Nabriva Therapeutics AG-Phase II, 2015 10

Nabriva Therapeutics AG-Phase I, 2015 11

Nabriva Therapeutics AG-Preclinical, 2015 12

Nabriva Therapeutics AG-Pipeline by Target, 2015 17

Nabriva Therapeutics AG-Pipeline by Route of Administration, 2015 18

Nabriva Therapeutics AG-Pipeline by Molecule Type, 2015 19

Nabriva Therapeutics AG-Pipeline Products by Mechanism of Action, 2015 20

Nabriva Therapeutics AG-Recent Pipeline Updates, 2015 21

Nabriva Therapeutics AG-Dormant Developmental Projects,2015 23

Nabriva Therapeutics AG, Subsidiaries 24

List of Figures

Nabriva Therapeutics AG-Pipeline by Top 10 Indication, 2015 6

Nabriva Therapeutics AG-Pipeline by Stage of Development, 2015 8

Nabriva Therapeutics AG-Monotherapy Products in Pipeline, 2015 9

Nabriva Therapeutics AG-Pipeline by Top 10 Target, 2015 17

Nabriva Therapeutics AG-Pipeline by Top 10 Route of Administration, 2015 18

Nabriva Therapeutics AG-Pipeline by Top 10 Molecule Type, 2015 19

Nabriva Therapeutics AG-Pipeline Products by Top 10 Mechanism of Action, 2015 20

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@]

Current R&D Portfolio of Nabriva Therapeutics AG; Nabriva Therapeutics AG - Key Therapeutics; Nabriva Therapeutics AG - Pipeline Overview and Promising Molecules; Nabriva Therapeutics AG - News; Nabriva Therapeutics AG - Latest Updates; Nabriva Therapeutics AG - Pipeline; Nabriva Therapeutics AG - Discontinued/Dormant Projects

Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

query [@]